GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Avanir Pharmaceuticals (AVNR) [hlAlert]

Rating:
Buy AVNR
up 797.35 %

Avanir Pharmaceuticals (AVNR) rated Buy by Merriman

Posted on: Friday,  Jan 29, 2010  8:25 AM ET by Merriman

Merriman rated Buy Avanir Pharmaceuticals (NASDAQ: AVNR) on 01/29/2010, when the stock price was $1.89. Since
then, Avanir Pharmaceuticals has gained 797.35% as of 01/12/2015's recent price of $16.96.
If you would have followed this Merriman's recommendation on AVNR, you would have gained 797.35% of your investment in 1809 days.

Avanir Pharmaceuticals is a pharmaceutical company focused on developing, acquiring and commercializing therapeutic products for the treatment of chronic diseases. The Company?s product candidates address therapeutic markets that include the central nervous system and inflammatory diseases. Its principal product candidate, Zenviatm (dextromethorphan hydrobromide/quinidine sulfate), is in Phase III clinical development for the treatment of pseudobulbar affect (PBA) and diabetic peripheral neuropathic pain (DPN pain). The Company?s first commercialized product, docosanol 10% cream, (sold as Abreva by its marketing partner GlaxoSmithKline Consumer Healthcare in North America) is an over-the-counter treatment for cold sores that has been approved by the United States Food and Drug Administration (FDA).

Merriman provides advanced tools for acquiring such information. These tools integrate a combination of cycles, geocosmic signatures and trend analysis patterns in assisting the serious investor in their interpretation of the various financial markets and the general economy. In today's fast paced and seemingly chaotic marketplace, you need the edge that only a broader analysis of human activity can provide.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/29/2010 8:25 AM Buy
None
1.89
as of 12/31/2010
1 Week down  -2.58 %
1 Month down  -2.58 %
3 Months up  29.78 %
1 YTD up  119.04 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy